WeLeader Biomedical Co., Ltd. (7713.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
70.60 TWD
Market cap
3.21 bn TWD
P/E (2025)
15.40
P/S (2025)
2.89
Dividend yield
5.81 %
Net margin
18.80 %
Return on equity (ROE)
16.55 %
Return on assets (ROA)
8.52 %

WeLeader Biomedical Co., Ltd. financials

Fiscal year20242025
Revenue991.13 m TWD1.11 bn TWD
Gross profit316.32 m TWD370.97 m TWD
Operating income214.20 m TWD261.13 m TWD
EBIT221.00 m TWD269.00 m TWD
Net income170.21 m TWD208.56 m TWD
Diluted EPS – continuing operations4.09 TWD4.59 TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About WeLeader Biomedical Co., Ltd.

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT central laboratory products, and CCM fully automated track processing products. It serves research institutions, schools, hospitals, laboratories, and hospitals. The company was founded in 1992 and is headquartered in Kaohsiung, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.